After finishing at $5.43 in the prior trading day, Aurinia Pharmaceuticals Inc (NASDAQ: AUPH) closed at $5.37, down -1.10%. In other words, the price has decreased by -$0.06 from its previous closing price. On the day, 1413899 shares were traded. AUPH stock price reached its highest trading level at $5.56 during the session, while it also had its lowest trading level at $5.34.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
Our goal is to gain a better understanding of AUPH by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 4.99 and its Current Ratio is at 5.50. In the meantime, Its Debt-to-Equity ratio is 0.26 whereas as Long-Term Debt/Eq ratio is at 0.22.
Oppenheimer Upgraded its Perform to Outperform on December 10, 2021, whereas the target price for the stock was revised from $33 to $31.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 06 ’24 when Greenleaf Peter sold 126,981 shares for $5.60 per share. The transaction valued at 711,094 led to the insider holds 1,522,114 shares of the business.
Robertson Stephen P. sold 57,745 shares of AUPH for $323,372 on Mar 06 ’24. The EVP, General Counsel now owns 443,824 shares after completing the transaction at $5.60 per share. On Mar 06 ’24, another insider, Donley Matthew Maxwell, who serves as the EVP, Ops & Strategy of the company, sold 40,665 shares for $5.51 each. As a result, the insider received 224,064 and left with 584,072 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, AUPH now has a Market Capitalization of 786.00M and an Enterprise Value of 533.12M. For the stock, the TTM Price-to-Sale (P/S) ratio is 4.42 while its Price-to-Book (P/B) ratio in mrq is 2.04. Its current Enterprise Value per Revenue stands at 3.04 whereas that against EBITDA is -8.46.
Stock Price History:
Over the past 52 weeks, AUPH has reached a high of $12.43, while it has fallen to a 52-week low of $5.35. The 50-Day Moving Average of the stock is 7.32, while the 200-Day Moving Average is calculated to be 8.67.
Shares Statistics:
The stock has traded on average 2.54M shares per day over the past 3-months and 1.79M shares per day over the last 10 days, according to various share statistics. A total of 143.83M shares are outstanding, with a floating share count of 127.57M. Insiders hold about 11.79% of the company’s shares, while institutions hold 36.53% stake in the company. Shares short for AUPH as of Feb 15, 2024 were 16.85M with a Short Ratio of 6.64, compared to 16.39M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 11.65% and a Short% of Float of 11.69%.
Earnings Estimates
Its stock is currently analyzed by 6 different market analysts. On average, analysts expect EPS of -$0.14 for the current quarter, with a high estimate of $0.01 and a low estimate of -$0.2, while EPS last year was -$0.18. The consensus estimate for the next quarter is -$0.02, with high estimates of $0.04 and low estimates of -$0.06.
Analysts are recommending an EPS of between $0.15 and -$0.34 for the fiscal current year, implying an average EPS of -$0.05. EPS for the following year is $0.39, with 6 analysts recommending between $0.83 and -$0.14.
Revenue Estimates
6 analysts predict $47.45M in revenue for the current quarter. It ranges from a high estimate of $51.82M to a low estimate of $46M. As of the current estimate, Aurinia Pharmaceuticals Inc’s year-ago sales were $34.41M, an estimated increase of 37.90% from the year-ago figure.
A total of 6 analysts have provided revenue estimates for AUPH’s current fiscal year. The highest revenue estimate was $232.83M, while the lowest revenue estimate was $207M, resulting in an average revenue estimate of $224.25M. In the same quarter a year ago, actual revenue was $175.51M, up 27.80% from the average estimate. Based on 6 analysts’ estimates, the company’s revenue will be $288.87M in the next fiscal year. The high estimate is $339.89M and the low estimate is $250M. The average revenue growth estimate for next year is up 28.80% from the average revenue estimate for this year.
